Introduction
Over the past two decades, the Food and Drug Administration (FDA) has approved several different types of immunotherapies as treatment options for patients with cancer, secondary to reports of improved survival, and complete remissions in some cancers. [1] [2] [3] [4] [5] [6] [7] Immunotherapy uses the body's immune system to combat cancer; specifically, it stimulates the production of specific antibodies or counteracts malignant cells' production of signals or pathways that suppress immune responses.
and other therapies that manipulate T-cell activation causing autoimmune toxicity. [9] Occurring in any system of the body, these AEs range from mild to life-threating in severity, depending on the type of immunotherapy, route of administration, and mechanism of action. [10, 11] Unlike the AEs of conventional chemotherapy, which have a predictable nadir or cyclic pattern after administration, AEs related to these newer versions of immunotherapy are variable in regard to their onset and resolution and may be present at any time, from a period of a few weeks during administration of treatment to several months after completion of treatment. [12] Therefore, improving outcomes in patients undergoing oncologic immunotherapy requires oncology nurses' knowledge and understanding of the various immunotherapy agents, as well as early recognition and management of potential AEs, especially AEs associated with checkpoint inhibitors and other agents that manipulate T-cell activation causing autoimmune toxicity. This article draws upon current evidence from systemic reviews, meta-analyses, and expert consensus guidelines to provide a brief overview of common immunotherapies used in cancer and management of their associated AEs.
Categories of Immunotherapy
The major oncologic immunotherapies involve cancer vaccines, monoclonal antibodies (mAbs), chimeric antigen receptor (CAR) T-cell therapy, cytokines, oncolytic viral immunotherapy, and immune checkpoint inhibitors. [11] Given the variability in mechanism of action of the different immunotherapies and the heterogeneity of AEs, it is imperative that oncology nurses become familiar with the current version of The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v. 5.0), which is a standardized list of AE terms commonly found in oncology. The CTCAE is available in detail at https://ctep. cancer.gov/protocolDevelopment/electronic_applications/ docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. The CTCAE serves as a universal tool for oncology nurses to properly gauge or measure the severity of the AE, track the progress of the AE, document the AEs in standardize terminology, and help oncology nurses to initiate the proper treatment for the AEs based on the CTCAE grade and the established guidelines and algorithms.
Cancer vaccines
Cancer vaccines stimulate or restore the immune system's ability to target peptides or antigens on cancer cells. [13] Generally, these biological response modifiers are categorized as cell-based, peptide-based, tumor-cell-based, or immune-or dendritic-cell-based vaccines. [10] Currently, sipuleucel-T (Provenge; Dendreon Pharmaceuticals) is the only therapeutic dendritic-cell-based vaccine that has received FDA approval for the treatment of hormone-refractory prostate cancer. [14] Sipuleucel-T uses the patient's own cells to induce an immune response against prostatic acid phosphatase (PAP), which is found in 95% of prostate adenocarcinomas and is specific to prostate tissue. [15] Sipuleucel-T is made by harvesting the patient's peripheral blood mononuclear cells using leukapheresis. The cells are then sent to the laboratory, where they are cultured in vitro for 36-44 h with a fusion protein, composed of recombinant PAP and granulocyte-macrophage-colony-stimulating factor (GM-CSF), and then reinfused back into the patient. [14] Normally, this process is replicated every 2 weeks for a total of three doses. [15] Generally, sipuleucel-T is well tolerated; however, common AEs experienced by patients participating in sipuleucel-T clinical trials include chills (44.0%-57.8%), pyrexia (29.3%-36.2%), headache (16.0%-23.3%), myalgia (9.8%-21.6%), influenza-like illness (9.8%-13.8%), and hypertension (7.4%-11.2%). [15] One clinical trial reported groin pain (5%), vomiting (10.9%), dyspnea (10.9%), asthenia (5.3%-14.3%), and hyperhidrosis. [15] Other reported AEs include stroke, myocardial infarction, and increased risk of deep vein thrombosis. [16] However, most AEs associated with sipuleucel-T are infusion related which are caused by a release of cytokines. [17] Usually, infusion-related AEs are self-limiting and resolve within 24-48 h after vaccine infusion. [10] To minimize infusion-related AEs, the European Society for Medical Oncology clinical practice guidelines recommends premedication with acetaminophen and diphenhydramine and adjustment in the infusion rate of sipuleucel-T [ Table 1 ]. [15, [17] [18] [19] [20] [21] [22] [23] [24] [25] Monoclonal antibodies mAbs are cell-derived, laboratory-generated substances that target specific antigens on tumors. [8] mAbs -which may be murine (made from mice), chimeric (part mouse and part human), humanized (mouse antibodies attached to human antibodies), or fully human (human antibodies) -hinder tumor growth by inhibiting tumor cells' survival cascades, interfering with tumor angiogenesis, and enabling malignant cells to avoid programmed cell death (PD) and evade immune checkpoints. [26] To date, the FDA has approved several mAbs for the treatment of cancer [ Table 2 ]. [17, [26] [27] [28] [29] [30] [31] [32] [33] AEs associated with mAbs are specific to the pharmacologic mechanism of action [ Table 1 ], and their management depends on the mechanism of action and the route of administration [ Table 1] . [10, [26] [27] [28] [29] For example, mAb-related AEs can range from a mild headache, diarrhea, transient pruritus, and dermatitis to potentially serious or life-threatening AEs such as anaphylaxis, cardiovascular AEs, thromboembolic AEs, cytokine release Metastatic renal cell carcinoma Metastatic melanoma
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• Monitor vital signs, urine output, and weight. syndrome (CRS), hepatitis, pulmonary AEs, hemorrhage, and cytopenias. [30, 34] While the mechanism behind some mAbs AEs such as cytopenias is unclear, AEs such as Stevens-Johnson syndrome, urticaria, serum sickness, and anaphylaxis are generally mediated by the immune system. [33] The mechanism behind pulmonary AEs such as interstitial pneumonitis, acute respiratory distress syndrome, hypersensitivity pneumonitis, or bronchiolitis obliterans organizing pneumonia is a result of activation of cytotoxic T-lymphocytes, which leads to alveolar and vascular damage, cytokine release, and likely cross-reaction between lung and tumor antigens. [33] In contrast, cardiac AEs are believed to result from the inhibition of a growth factor (neuregulin 1) which is needed for cardiac development and maintenance. [33] Similarly, AE such as acneiform rash which occurs in 50%-100% of patients receiving cetuximab and panitumumab is a result of the inhibition of epidermal growth factor receptor (EGFR) which initiates the alteration and rupture of the epithelial barrier, which in turn facilitates bacterial access and proliferation. [33] AEs (hypertension, hemorrhage, and thromboembolism) associated with mAbs that target vascular endothelial growth factor (VEGF) and VEGF receptor are a result of the disruption of physiological processes involved in wound healing, blood pressure regulation, coagulation, renal filtration, and vascular homeostasis. [31] Other frequently reported AEs of mAbs are infusion related and a result of antigen-antibody interactions precipitating cytokine release. [17, 30] Infusion-related AEs can occur within 30 min to 2 h after the infusion or 24 h later and are described as pruritus, chills, fever, asthenia, dyspnea, nausea, rash, or headache. [30, 34] Severe and potentially fatal infusion-related AEs may occur in 0.3% of patients and present as angioedema, hypotension, bronchospasm, and cardiac arrest. [30, 34] Furthermore, the incidence of infusion-related AEs varies among different mAbs. For example, rituximab is 77%, trastuzumab is 40%, cetuximab is 15%-20%, bevacizumab is <3%, and panitumumab is 3%. [33] Management of infusion-related AEs is based on well-established clinical practice guidelines by the European Society for Medical Oncology. [17] Chimeric antigen receptor T-cells CAR T-cells are genetically engineered T-cells reprogrammed to produce CARs on the cell membrane. [8, 35] Once these cells have been collected from the patient's blood, reprogrammed, and injected back into the patient, tumor-specific recognition occurs, and then, T-cell memory enables the T-cells to proliferate, destroy tumor cells, and Contd... • Assess for signs and symptoms of infection.
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• Monitor complete blood counts frequently. conduct surveillance. [36] The FDA has approved two CAR T-cell therapies: (1) axicabtagene ciloleucel (Yescarta: Kite, Santa Monica, CA) for adult patients with diffuse large B-cell lymphoma who have relapsed after two other kinds of treatment and (2) tisagenlecleucel (Kymriah: Novartis, Switzerland) for children and young adults with B-cell acute lymphoblastic leukemia. [37] A common AE associated with CAR T-cell therapy is CRS, with incidence rates of 43%-100% in adult and pediatric patients with relapsed and refractory acute lymphoblastic leukemia. [18, [38] [39] [40] CSR occurs when T-cells engage with a target antigen, multiply in the body, and release cytokines that cause an inflammatory response. [18] The onset and severity of CRS depend on the type of CAR T-cell therapy and the degree of immune cell activation. [19] Typically, CRS symptoms, if they occur, develop days to weeks after infusion of CAR T-cell therapy. [19] Patients with CRS may experience constitutional symptoms such as fever, rigors, malaise, myalgias, arthralgias, fatigue, nausea, vomiting, and headache, while other patients may develop severe symptoms such as hypotension, tachycardia, capillary leak syndrome, and multiorgan dysfunction. [18, 19, [38] [39] [40] [41] In addition, patients may experience neurotoxicity, also known as immune effector cell-associated neurotoxicity syndrome, which can occur concurrently with or after CSR, and vary from mild, expressive aphasia to confusion, lethargy, agitation, delirium, difficulty concentrating, seizures, encephalopathy, and infrequently, cerebral edema. [19, 42] In a trial conducted by Schuster et al., in which 28 patients with diffuse large B-cell lymphoma or follicular lymphoma that had relapsed or was refractory to previous treatment were treated with CAR T-cell therapy, CRS occurred in 16 patients and neurotoxicity (ranging from mild cognitive disturbance to global encephalopathy) occurred in 11 patients. [42] In this study, CRS and neurotoxicity were self-limiting in all patients but one, who was given tocilizumab (Actemra: Genentech, South San Francisco, CA, USA), an anti-interleukin (IL)-6 antibody that reversed the symptoms of CRS within a few hours. [42] A similar study of 161 patients (133 patients completed the toxicity assessment) with acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma treated with CAR T-cell therapy reported that CRS developed in 71% of patients and that neurotoxicity was observed in 40% of patients. [43] In this study, CRS and neurotoxicity were reversible except six patients who died. [43] Management of CRS depends on the grading as outlined in consensus guidelines established by a CAR T-cell therapy-associated toxicity working group and the American Society for Blood and Marrow Transplant [ Table 1 ]. [20, 44] Opinions vary on the need for hospitalization; Neelapu et al. recommended hospitalization and close monitoring of patients for a period of 7 days after CAR T-cell infusion, whereas Teachey et al. posited that patients can receive CAR T-cells in the outpatient setting and be admitted to the hospital only if the patient develops a fever. [20, 45] 
Cytokines
Cytokines, which are small protein molecules naturally produced by the body, regulate the differentiation, migration, activation, and suppression of leukocytes. [13] Of the several different varieties of cytokines, recombinant interferon alpha-2b (IFN-alpha-2b) and IL-2 are the most widely used cytokines in cancer treatment. [21] Recombinant IFN-alpha-2b has been approved for non-Hodgkin's lymphoma, hairy cell leukemia, and melanoma. [46] Recombinant IFN-alpha-2b is associated with flu-like symptoms, such as chills, fever, headache, and myalgia, [10, 22] which are generally controlled with nonsteroidal anti-inflammatory drugs. [47] Other potential AEs include anorexia, depression, fatigue, hepatic dysfunction, thyroid dysfunction, autoimmune hemolytic anemia/thrombocytopenia, and immune-mediated nephritic syndrome. [10, 48] Patients with grade 2-3 fatigue may require a break from treatment or a dose reduction, and patients with depression may require prophylactic antidepressants. [47] Generally, AEs associated with IFN-alpha-2b tend to reverse rapidly when therapy is discontinued. [10] IL-2 is a T-cell growth factor that promotes the antitumor activity of natural killer cells, enhances the growth and proliferation of regulatory T-cells (Tregs), and induces lymphokine-activated killer cells that mediate antitumor effects. [13] IL-2 has been approved for the treatment of metastatic melanoma and metastatic renal cell cancer and can be administered intravenously or subcutaneously. [49] Common AEs associated with IL-2 include chills, fatigue, fever, nausea, diarrhea, vomiting, hypotension, transaminitis, dyspnea, oliguria, and hyperbilirubinemia. [10, 23] In a retrospective analysis of 243 patients with advanced melanoma who received high-dose IL-2, the following AEs were reported: oliguria (14%-58%), hypotension (14%-39%), and tachycardia (10%-21%). [50] Given that these AEs can be severe or life-threatening, most patients are administered high-dose IL-2 on an inpatient unit with cardiac monitoring at institutions that have healthcare providers who have experience in recognizing and managing these AEs using specific institutional guidelines and standing orders [ Table 1 ]. [10, 23, 24] 
Oncolytic viral therapy
Oncolytic viral therapy, which increases a patient's immune response to cancer without harming normal tissue, uses a modified virus that can force tumor cells to self-destruct and release antigens. [13] In 2015, talimogene laherparepvec (T-VEC) (Imlygic: Amgen, Thousand Oaks, CA, USA), a second-generation oncolytic herpes simplex type 1, was engineered to express human GM-CSF, received FDA approval for use in patients with advanced melanoma. [51] The mechanism of action of T-VEC is unknown; however, it is thought that T-VEC uses the herpes virus entry mediator, glycoproteins, and nectins on the cell surface to enter cancer cells and trigger cell lysis. [52] Common AEs associated with T-VEC are fever (42.8%), chills (48.6), fatigue (50.3%), nausea (35.6%), vomiting (21.2%), headache (18.8%), and erythema, pain, and cellulitis (27.7%) at the injection site. [51, 52] Management of AEs is mainly supportive; for example, acetaminophen or indomethacin can be given for pain, chills, or fever, and ice bags can be applied to the injection site 5-10 min before T-VEC injection to minimize pain at the injection site [ Table 1 ]. [25] 
Immune checkpoint inhibitors
Immune checkpoint inhibitors, which enhance the immune system's preexisting antitumor responses, target molecules that switch immune responses on and off. [8] For instance, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is normally expressed on the surface of naive effector T-cells and Tregs, which inhibit autoimmunity, and promotes tolerance to self-antigens. [53] Similarly, PD-1 is an immune inhibitory receptor which negatively regulates T-cell functions through the engagement of programmed death ligand 1 (PD-L1), which is found on varies malignant cells. [53] Hence, checkpoint inhibitors disrupt the signaling pathways that allow cancer cells to evade T-cell-mediated death by preventing CTLA-4 and PD-1 from binding with specific ligands, thus enhancing the immune system's ability to attack malignant cells. [54] The FDA has approved several checkpoint inhibitors that have shown clinical efficacy in the treatment of a number of cancers [ Table 3 ]. [54] [55] [56] [57] The AEs associated with checkpoint inhibitors are referred to as immune-related AEs (irAEs). [56] These irAEs are secondary to the infiltration of activated T-cells -which are also involved in autoimmunity -into normal tissue. [10] These irAEs can affect any organ or multiple organs simultaneously or at different time points. The areas most commonly affected are skin, gastrointestinal tract, endocrine, lungs, thyroid, pituitary, adrenal glands, and musculoskeletal system and less commonly affected are nervous, renal, hematologic, ocular, and cardiovascular system. [47, 56, [58] [59] [60] [61] For example, in a retrospective study of 50 patients with nonsmall cell lung cancer, who were treated with an immune checkpoint inhibitor, the most frequent irAEs were fatigue (42%), rash (22%), nausea (20%), and fever (20%). [62] Similarly, a retrospective analysis to assess the safety profile of nivolumab in 576 patients with advanced melanoma found that 71% of patients experienced irAEs, with the most common irAEs being fatigue (25%), pruritus (17%), diarrhea (13%), and rash (13%). [63] The management of irAEs is based on well-established clinical practice guidelines, such as the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the European Society for Medical Oncology, and the Society for Immunotherapy of Cancer. [58, 60, 64, 65] For patients with grade 1 irAEs that are not cardiac, hematologic, or neurologically related, they continue checkpoint inhibitors with close monitoring. For patients with grade 2 irAEs, the checkpoint inhibitor should be put on hold and corticosteroids may be given; the checkpoint inhibitor may be resumed when the patient's symptoms and/or laboratory values return to grade 1 or less. For patients with grade 3 irAEs, the checkpoint inhibitor should be placed on hold and high-dose corticosteroids should be administered and tapered over 4-6 weeks; if symptoms do not improve within 48-72 h, administer infliximab; however, if symptoms and/or laboratory values return to grade 1 or less, the checkpoint inhibitor may be resumed with caution. For patients with grade 4 irAEs -except for endocrinopathies that are controlled with hormone replacement -the checkpoint inhibitor should be permanently discontinued [ Figure 1 ]. [58] Since check inhibitors can cause irAEs to occur in any organ of the body, potentiate autoimmune diseases, or aggravate other comorbid diseases, patients should be thoroughly screened and examined before starting an immune checkpoint inhibitor. [60] Furthermore, patients and caregivers should be educated in early recognition and management of irAEs to minimize serious or life-threatening complications. [66] A complete patient educational guide on irAEs can be accessed at https://www.esmo.org/Patients/Patient-Guides/ Patient-Guide-on-Immunotherapy-Side-Effects. [58] 
Combination immunotherapy
Although immunotherapy has changed the landscape of cancer treatment, one of the biggest challenges of this type of treatment is that many patients do not benefit from it (i.e. they have primary resistance) and some patients relapsed after a period of response (i.e., they develop acquired resistance). [67] To overcome this challenge, researchers are using strategies such as combining anti-PD-1 or PD-L1 agents with other immunotherapy agents, molecular targeted therapy, vaccines, chemotherapies, radiotherapy, or chemoradiotherapies. [57] As of September 2017, over 1, 105 combination immunotherapy clinical trials were in progress; however, only one checkpoint inhibitor combination, nivolumab (Opdivo) with ipilimumab (Yervoy), has been approved for clinical use. [57] As checkpoint inhibitors are combined with other immunotherapy agents or other treatment modalities, the likelihood of more severe or newer AEs occurring increases. [66] For example, a systematic review that assessed the clinical, epidemiological, humanistic, and economic burden of gastrointestinal AEs due to combination checkpoint inhibitors in advance melanoma reported that patients who received combination of ipilimumab plus nivolumab experienced more AEs than patients who received monotherapy checkpoint inhibitors. [68] Similarly, an observational study of patients with nonsmall cell lung cancer receiving nivolumab plus an EGFR-tyrosine kinase inhibitor (TKI) reported higher incidents of interstitial pneumonitis for nivolumab in combination with EGFR-TKI versus treatment with either drug alone. [69] 
Conclusion
Because of the variability in the mechanism of action among the major categories of oncologic immunotherapy treatments, and because of the heterogeneity of AEs, it is imperative that oncology nurses become familiar with the different AEs so that they can initiate appropriate management and referrals to specialist to improve patient outcomes. Oncology nurses need to be on the forefront of assessing and documenting AEs and the long-term impact on patients, which may lead to a better understanding of why some patients develop AEs and how they can be predicted and alleviated in patients with cancer.
